Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178484 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL12564549 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL12640899 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL1987472 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL6612597 | 0.84 | EPHX1 (0.63) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL4639581 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GAACPB1CTSKTSHR | |
| SCHEMBL18029925 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GAACPB1CTSKTSHR | |
| SCHEMBL19345760 | 0.84 | EPHX1 (0.57) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL22585844 | 0.81 | CASP3 (0.58) | ALDH1A1GAACPB1CTSBCTSS | |
| SCHEMBL2848373 | 0.81 | ALDH1A1 (0.58) | ALDH1A1GAACPB1CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| EP-2516434-B1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ALDH1A1 824/4885GAA 2316/4885CPB1 3844/4885 |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | SYK, BTK, LYN | ALDH1A1 1660/4885GAA 2421/4885CPB1 3468/4885 |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ALDH1A1 824/4885GAA 2316/4885CPB1 3844/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ALDH1A1 824/4885GAA 2316/4885CPB1 3844/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | ALDH1A1 824/4885GAA 2316/4885CPB1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.